These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 31343615

  • 1. Clinicopathological features and outcomes after radioactive iodine treatment of oncocytic well-differentiated thyroid carcinomas.
    Amouri W, Charfeddine S, Charfi S, Jardak I, Boudawara T, Guermazi F.
    Nucl Med Commun; 2019 Sep; 40(9):888-893. PubMed ID: 31343615
    [Abstract] [Full Text] [Related]

  • 2. Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome.
    Lukovic J, Petrovic I, Liu Z, Armstrong SM, Brierley JD, Tsang R, Pasternak JD, Gomez-Hernandez K, Liu A, Asa SL, Mete O.
    Front Endocrinol (Lausanne); 2021 Sep; 12():795184. PubMed ID: 34975765
    [Abstract] [Full Text] [Related]

  • 3. Hürthle cell carcinoma: a clinicopathological study of thirteen cases.
    Ozlem Küçük N, Kulak H, Tokmak E, Tar P, Ibiş E, Aras G.
    Nucl Med Commun; 2006 Apr; 27(4):377-9. PubMed ID: 16531925
    [Abstract] [Full Text] [Related]

  • 4. Long-term outcome of rare oncocytic papillary (Hürthle cell) thyroid carcinoma following (adjuvant) initial radioiodine therapy.
    Wenter V, Jellinek A, Unterrainer M, Ahmaddy F, Lehner S, Albert NL, Bartenstein P, Knösel T, Spitzweg C, Ilhan H, Todica A.
    Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2526-2535. PubMed ID: 31410542
    [Abstract] [Full Text] [Related]

  • 5. The role of radioactive iodine in the treatment of Hürthle cell carcinoma of the thyroid.
    Besic N, Vidergar-Kralj B, Frkovic-Grazio S, Movrin-Stanovnik T, Auersperg M.
    Thyroid; 2003 Jun; 13(6):577-84. PubMed ID: 12930602
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Radioactive Iodine Treatment Is Associated with Improved Survival for Patients with Hürthle Cell Carcinoma.
    Jillard CL, Youngwirth L, Scheri RP, Roman S, Sosa JA.
    Thyroid; 2016 Jul; 26(7):959-64. PubMed ID: 27150319
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Long-Term Outcomes and Prognoses of Elderly Patients (≥65-Years-Old) With Distant Metastases From Well-Differentiated Thyroid Cancer During Radioiodine Therapy and Follow-Up.
    Qiu ZL, Shen CT, Sun ZK, Song HJ, Xi C, Zhang GQ, Wang Y, Luo QY.
    Front Endocrinol (Lausanne); 2020 Jul; 11():588024. PubMed ID: 33716950
    [Abstract] [Full Text] [Related]

  • 15. High-Dose RAI Therapy Justified by Pathological N1a Disease Revealed by Prophylactic Central Neck Dissection for cN0 Papillary Thyroid Cancer Patients: Is it Superior to Low-Dose RAI Therapy?
    Wei L, Bai L, Zhao L, Yu T, Ma Q, Ji B.
    World J Surg; 2019 May; 43(5):1256-1263. PubMed ID: 30684002
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer.
    Iizuka Y, Katagiri T, Ogura K, Mizowaki T.
    Ann Nucl Med; 2019 Jul; 33(7):495-501. PubMed ID: 30955202
    [Abstract] [Full Text] [Related]

  • 19. Hürthle cell carcinoma.
    Yutan E, Clark OH.
    Curr Treat Options Oncol; 2001 Aug; 2(4):331-5. PubMed ID: 12057113
    [Abstract] [Full Text] [Related]

  • 20. Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy.
    Piccardo A, Puntoni M, Bottoni G, Treglia G, Foppiani L, Bertoli M, Catrambone U, Arlandini A, Dib B, Altrinetti V, Massollo M, Bossert I, Cabria M, Bertagna F, Giovanella L.
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):926-934. PubMed ID: 27966046
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.